



Early Mobilization After Pacemaker Implantation.

Šedlák J., Brada M., Vančura V.,
Kučera R.

Department of Cardiology, University
Hospital and Faculty of Medicine
Brno






- There are not any recommendations (professional societies or corporate) specifying the duration of immobilization after CIED implantation.
- Time of immobilization is based on the historical concept from the time of implantation leads with passive fixation and varies in different hospitals.




Early mobilization after permanent pacemaker implantation

- FN Brno
 - After the procedure, the patient returns to his bed. the day of the implantation we recommend a more restful regime, the next days after the procedure a normal movement regime.
- IKEM
 - To reduce the risk of dislodgement of the lead, it is important to maintain bed rest, usually until the next day, and then minimize movements of the upper limb on the side where the pacemaker is implanted.
- FN Bulovka
 - The patient should spend the next 24 hours at rest in hospital bed.



Early Mobilization After Pacemaker Implantation



Study design

prospective, randomized, single-center study that enrolled patients undergoing pacemaker implantation at our institution.




Inclusion criteria

- (1) Minimum age of 18 years
- (2) class I and II recommendations for pacing according to ESC guidelines
- (3) mobile, cooperative patients
- (4) signed informed consent for the study




Exclusion criteria

- (1) implantation of CRT devices
- (2) device upgrade or revision
- (3) patients with the usual contraindications to permanent pacemaker implantation
- (4) pregnancy.



Early Mobilization after Pacemaker Implantation



Early Mobilization After Pacemaker Implantation

- The primary composite endpoint
 - Included the most commonly encountered complications associated with CIED implantation.
 - Hematoma, major bleeding (requiring intervention/revision, blood transfusion, or prolonged hospitalization)
 - Wound infection
 - Pneumothorax
 - Atrial lead dislodgement
 - Ventricular lead dislodgement
 - Other, extracardiac complications
- The secondary endpoint
 - compared the incidence of each complication listed as part of the primary composite endpoint and any changes in the technical parameters of the CIEDs.



Patients characteristics

	Total	Early mobilization		Late mobilization		p
		n	%	n	%	
Randomization short x long	200	100		100		
Age	74,89	74,85		74,94		
Male	121	61	50,4%	60	49,6%	
Female	79	39	49,4%	40	50,6%	
Indication						
Sick sinus syndrome	71	38	53,5%	33	46,5%	0.679
AV block	79	37	46,8%	42		0.6907
AF with bradycardia	50	25	50%	25	50%	
Type of device						
Single chamber pacemaker	50	25	50%	25	50%	
Dual chamber pacemaker	150	75	50%	75	50%	
Medication						
Warfarin	59	29	49,2%	30	50,8%	
Rivaroxaban	33	17	51,5%	16	48,5%	
Dabigatran	9	8	88,9%	1	11,1%	0.036
Apixaban	14	8	57,1%	6	42,9%	0.7835
Edoxabam	0	0	0%	0	0%	
Anopyrin	50	17	34%	33	66%	0.0567
Trombex	7	3	42,9%	4	57,1%	
Brilique	3	2	66,7%	1	33,3%	
Prasugrel	0	0	0%	0	0%	

Results – technical parameters

	EaM	LaM	EaM	LaM	EaM	LaM	p
	Discharge	follow-up	1 - month follow-up		6 - month follow-up		Discharge FU/6M FU
A sensing (mV)	2,29	2,57	2,79	2,88	2,48	2,73	0,30
V sensing (mV)	11,59	11,97	13,87	13,11	12,92	12,17	0,70
A threshold (V)	0,52	0,52	0,55	0,53	0,61	0,55	1
V threshold (V)	0,68	0,62	0,76	0,79	0,76	0,82	0,29
A impedance (ohm)	410,09	413,71	410,11	408,43	390,69	390,97	0,94
V impedance (ohm)	752,53	758,66	686,80	690,48	651,29	637,21	0,91


- The technical parameters (sensing, threshold, and impedance) were stable over the course of the follow-up in both arms of our trial and no significant variation in the evolution of sensing, threshold, or impedance values was found.




Results – complications

	Total	Early mobilization		Late mobilization		p (Fisher exact test)
		n	%	n	%	
Primary composite endpoint	11	4	0	7	0	0.5378
Haematoma, major bleeding	0	0	0%	0	0%	NS
Pneumothorax	2	0	0%	2	100%	0.4957
Atrial lead dislodgement	4	2	50%	2	50%	NS
Ventricular lead dislodgement	0	0	0%	0	0%	NS
Wound infection	1	1	100%	0	0%	NS
Perforation	1	0	0%	1	100%	NS
Others complications	3	1	33%	2	66%	NS

- Other complications (Upper arm thrombosis, lead fracture, upgrade to ICD) - thrombosis and fracture in long arm of immobilization
- 6 deaths occurred before 6 month follow-up (Covid 2x, cancer 1x, sepsis 1x, heart failure 1x, unknown 1x)



Early Mobilization After Pacemaker Implantation



Achieving a larger number of events would require the involvement of most implant centres in the Czech Republic within one year.

et al. European Society of Cardiology: cardiovascular disease statistics 2021.

et al.; 2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy



Incidence of complications after CIED therapy	%
Lead-related reintervention ^{354,639-690,692,695,700,701} (including dislodgement, malposition, subclavian crush syndrome, etc.)	1.0–5.9
CIED-related infections, <12 months ^{354,639,641,645,685,695,702}	0.7–1.7
Superficial infection ³⁵⁴	1.2
Pocket infections ³⁵⁴	0.4
Systemic infections ³⁵⁴	0.5
CIED-related infections, >12 months ^{702–709}	1.1–4.6
Pocket infections ⁷⁰²	1.3
Systemic infections ^{702,705}	0.5–1.2
Pneumothorax ^{354,658,690,692,700,701,707}	0.5–2.2
Haemothorax ⁶⁹⁵	0.1
Brachial plexus injury ⁶⁹⁵	<0.1
Cardiac perforation ^{354,663,690,692,695}	0.3–0.7
Coronary sinus dissection/perforation ^{710,288}	0.7–2.1
Revision due to pain/discomfort ^{354,690}	0.1–0.4
Diaphragmatic stimulation requiring reintervention ^{711,712,665,713}	0.5–5
Haematoma ^{354,639,650,652,654,690,700,714,715}	2.1–5.3
Tricuspid regurgitation ^{716–718}	5–15
Pacemaker syndrome ^{146,701,719}	1–20
Generator/lead problem ^{354,639,690}	0.1–1.5
Deep venous thrombosis (acute or chronic) ^{354,720,721}	0.1–2.6
Any complication ^{354,639,690,692,695,707,722,723}	5–15
Mortality (<30 days) ^{354,694}	0.8–1.4

CIED = cardiovascular implantable electronic device.

Outcomes of an expedited same-day discharge protocol following cardiac implantable electronic device (CIED) implantation

Received: 09 January 2024

[Cite this article](#)



[Journal of Interventional Cardiac
Electrophysiology](#)

[Aims and scope](#) →

[Submit manuscript](#) →

Methods

Observational, retrospective, multicentre study

Following CIED implantation at three centers between 2015 and 2021. Patients were divided into same-day discharge (SDD) and delayed discharge (DD) cohorts. Adverse event data were obtained from electronic medical records.

Primary outcomes were complications including electrode failure requiring revision, pneumothorax, hemothorax, electrode dislodgement, electrode perforation with tamponade, and death within 30 days of the procedure. Results were compared between the two cohorts using a χ^2 test.

Results

Total of 4543 CIED implantation procedures: with 1557 patients (34%) included in the SDD cohort.

Of these, 89% had a permanent pacemaker implanted (89% 2 lead system), 31% ICD, 20.6% CRT-P or CRT-D.

Patients with SDD were relatively younger, more often male, and had fewer comorbidities than patients with DD.


The mean time to postoperative chest X-ray was 2.6 h. SDD had lower complication rates (1.3% vs 2.1%, $p = 0.0487$) and acute care utilization rates (9.6% vs 14.0%, $p < 0.0001$). There was no difference in infection rates at 90 days between cohorts.



Outcomes of an expedited same-day discharge protocol following cardiac implantable electronic device (CIED) implantation

Published: 09 January 2024

[Cite this article](#)



[Journal of Interventional Cardiac
Electrophysiology](#)

[Aims and scope](#) →

[Submit manuscript](#) →

Observed 30-day complications among all patients undergoing CIED implantation

Complication type	Total	SDD	DDD
Pericardial effusion	1	0	1
Lead dislodgement	62	17	45
Lead fracture	14	0	14
Lead perforation with effusion	6	3	3


- Most lead dislodgements were detected during the pre-discharge inspection of the device.
- The same-day, two-hour discharge protocol is safe and effective with low rates of complications, infections, and postoperative acute care utilization.





Conclusion

- Our trial presents compelling evidence that early mobilization after CIED implantation is safe and effective.
- The absence of significant differences in periprocedural complications between the EaM and LaM arms supports the feasibility of early discharge, which could lead to substantial healthcare savings and improved patient experiences.
- Our findings advocate for a reconsideration of current post-implantation care protocols and promote early mobilization as the new standard of care.



Thank you for your
attention.

Early Mobilization After Pacemaker Implantation

Sample Size Calculator

Determines the minimum number of subjects for adequate study power

[ClinCalc.com](#) » [Statistics](#) » Sample Size Calculator

Study Group Design

✓
vs.
Two independent
study groups

vs.
One study group
vs. population

Two study groups will each receive different treatments.

Primary Endpoint

✓
Dichotomous
(yes/no)

Continuous
(means)

The primary endpoint is **binomial** - only two possible outcomes.
Eg, mortality (dead/not dead), pregnant (pregnant/not)

Statistical Parameters

Anticipated Incidence

Group 1 3 %

Group 2 4 %

Incidence

Enrollment ratio 1

Type I/II Error Rate

Alpha 0.05

Power 80%

Reset

Calculate

RESULTS

Dichotomous Endpoint, Two Independent Sample Study

Sample Size

Group 1	5301
Group 2	5301
Total	10602

Study Parameters

Incidence, group 1	3%
Incidence, group 2	4%
Alpha	0.05
Beta	0.2
Power	0.8

[View Power Calculations](#)

Early Mobilization After Pacemaker Implantation

Sample Size Calculator

Determines the minimum number of subjects for adequate study power

[ClinCalc.com](#) » [Statistics](#) » Sample Size Calculator

Study Group Design



vs.

Two independent study groups

vs.

One study group vs. population

Two study groups will each receive different treatments.

Primary Endpoint



Dichotomous (yes/no)

Continuous (means)

The primary endpoint is binomial - only two possible outcomes.
Eg, mortality (dead/not dead), pregnant (pregnant/not)

Statistical Parameters

Anticipated Incidence

Group 1 3 %

Group 2 5 %

Incidence

Enrollment ratio

1

Type I/II Error Rate

Alpha 0.05

Power 80%

Reset

Calculate

RESULTS

Dichotomous Endpoint, Two Independent Sample Study

Sample Size

Group 1	1506
Group 2	1506
Total	3012

Study Parameters

Incidence, group 1	3%
Incidence, group 2	5%
Alpha	0.05
Beta	0.2
Power	0.8

[View Power Calculations](#)



